Du forlater nå GSKs nettsider

Denne lenken tar deg til en nettside som ikke tilhører GSK. GSK er ikke ansvarlig for, går ikke god for og aksepterer intet ansvar for informasjon eller meninger på nettsteder til tredjeparter




Go to Close Top

Most common adverse reactions

In TIVICAY (dolutegravir) Phase IIb and Phase III clinical studies the most common* treatment emergent adverse reactions were the following:1

Tivicay adverse reactions

*Definitions of frequencies: very common ≥ 1/10, common ≥1/100 to <1/10

Drug-drug interactions

TIVICAY has few significant interactions with commonly used medications.1-5

The table below is a useful guide to dosing TIVICAY concomitantly with other medications your patients may be taking.*

Tivicay drug-drug interactions

*The table is not exhaustive.
 §In paediatric patients the weight-based once daily dose should be administered twice daily if used in combination with these medications.1

 EFV: efavirenz
 NVP: nevirapine
 TPV/r: tipranavir/ritonavir

For a more comprehensive list of interactions, please see the HIV DDI database of University of Liverpool.


TIVICAY and dofetilide coadministration is contraindicated due to potential life-threatening toxicity caused by high dofetilide concentration.1

For further information on Tivicay safety, please see the Summary of Product Characteristics.


  1. TIVICAY preparatomtale.
  2. Fantauzzi A, Turriziani O, Mezzaroma I. Potential benefit of dolutegravir once daily: efficacy and safety. HIV/AIDS (Auckl). 2013;5:29-40. doi: 10.2147/HIV.S27765
  3. Teixeira R, Nascimento Y, Crespo D. Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions. Braz J Infect Dis. 2013;17(2):194-204.
  4. Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid- reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother. 2011;66(7):1567-1572.
  5. Kandel CE, Walmsley S. Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Design, Development and Therapy. 2015:9 3547-3555. doi: 10.2147/DDDT.S84850

TIVICAY trademark is owned by or licensed to the ViiV Healthcare group of companies.